ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase‐4, for the treatment of Type 2 diabetes mellitus

BACKGROUND AND PURPOSE: Dipeptidyl peptidase (DPP)‐4 inhibitors increase levels of glucagon‐like peptide‐1 (GLP‐1) and provide clinical benefit in the treatment of type 2 diabetes mellitus. As longer acting inhibitors have therapeutic advantages, we developed a novel DPP‐4 inhibitor, ZY15557, that h...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Pharmacol
Hlavní autoři: Jain, Mukul R, Joharapurkar, Amit A, Kshirsagar, Samadhan G, Patel, Vishal J, Bahekar, Rajesh H, Patel, Harilal V, Jadav, Pradip A, Patel, Pankaj R, Desai, Ranjit C
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2017
Témata:
Research Papers
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5481660/
https://ncbi.nlm.nih.gov/pubmed/28452143
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.13842
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky